ArticleThe British journal of dermatology2019

Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.

B E Strober et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.